It could be argued that Acadia have other pipeline priorities...

It could be argued that Acadia have other pipeline priorities including its obligations under its collaboration agreement with Stoke Theraputics as briefly indicated below:
January 10, 2022
General Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases –
^Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program– Acadia receives exclusive worldwide licenses for two additional preclinical programs:
^ Rett syndrome (MECP2) and undisclosed neurodevelopmental target– Combines Stoke’s TANGO research platform with Acadia’s expertise in neurology drug development and commercialization– Stoke receives a $60 million upfront payment and potential milestone payments of up to $907 million and royalties on future sales

*SAN DIEGO & BEDFORD, Mass.—(BUSINESS WIRE)—Jan. 10, 2022—Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Stoke Therapeutics, Inc. (Nasdaq: STOK) announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest
Kens